-

QIAGEN N.V. to Report Fourth Quarter and Full-Year 2020 Results

VENLO, The Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced today that it plans to release its report on results for the fourth quarter and full-year 2020 on Tuesday, February 9,at approximately 22:05 Central European Time (CET) / 16:05 Eastern Standard Time (EST).

A conference call is planned for Wednesday, February 10, at 15:00 CET / 9:00 EST, hosted by Thierry Bernard, Chief Executive Officer, and Roland Sackers, Chief Financial Officer.

Conference call and webcast details

Interested parties may listen to the call by dialing:

+1 646 828 8193 (U.S.), +44 (0)330 336 9411 (UK), +49 (0)69 2222 2018 (Germany).

To avoid waiting time, please join the event conference 5-10 minutes prior to the start time.

Conference ID: 2900586

The webcast will be accessible at:
https://globalmeet.webcasts.com/viewer/event.jsp?ei=1422345&tp_key=e2c7f9a1ee

A conference call replay will be available by using the following link:
https://globalmeet.webcasts.com/viewer/event.jsp?ei=1422345&tp_key=e2c7f9a1ee

Contact: IR@qiagen.com

About QIAGEN

QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D, and industrial applications, primarily forensics). As of September 30, 2020, QIAGEN employed more than 5,300 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com.

Contacts

John Gilardi
Vice President Head of Corporate Communications and Investor Relations
+49 2103 29 11711
+1 240 686 2222
Email: ir@qiagen.com

Phoebe Loh
Associate Director Investor Relations
+49 2103 29 11457
Email: ir@qiagen.com

Industry:

QIAGEN N.V.

FWB:QIA
Details
Headquarters: Venlo, Netherlands
CEO: Thierry Bernard
Employees: 5800
Organization: PUB
Revenues: US$ 1.97 billion (2023)
Net Income: US$ 341.3 million (2023)
Release Summary
QIAGEN N.V. to Report Fourth Quarter and Full-Year 2020 Results
Release Versions
English

Contacts

John Gilardi
Vice President Head of Corporate Communications and Investor Relations
+49 2103 29 11711
+1 240 686 2222
Email: ir@qiagen.com

Phoebe Loh
Associate Director Investor Relations
+49 2103 29 11457
Email: ir@qiagen.com

More News From QIAGEN N.V.

QIAGEN Completes U.S. QIAstat-Dx Bloodstream Infection Portfolio With FDA Clearance of New Bacteria Detection Panel

GERMANTOWN, Md. & VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that U.S. laboratories now have access to the complete QIAstat-Dx bloodstream infection portfolio following clearance of a new panel by the U.S. Food and Drug Administration (FDA). The new panel detects gram-negative bacteria and antibiotic resistance markers in about one hour, complementing the recently FDA-cleared QIAstat-Dx panel for gram-positive bacteria and fungi....

QIAGEN Launches QIAmini to Automate Small-Batch Sample Preparation

VENLO, Netherlands & GERMANTOWN, Md.--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of QIAmini, a compact automated sample preparation system designed to give research laboratories a time-saving and cost-efficient alternative to processing samples by hand. QIAmini is designed primarily for academic laboratories and other research customers processing smaller sample batches that do not require larger automated systems. QIAGEN estimates the ad...

QIAGEN Calls Extraordinary General Meeting for Appointment of Jonathan M. Pratt to Managing Board

VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it will hold an Extraordinary General Meeting of Shareholders on November 6, 2026, at 2:00 p.m. CET. Shareholders will be asked to vote on the appointment of Jonathan M. Pratt to the QIAGEN Managing Board after he joined QIAGEN as Chief Executive Officer on September 1, 2026. Subject to shareholder approval, Jon Pratt would join Roland Sackers, Chief Financial Officer, as the two me...
Back to Newsroom